Ecofibre Limited
EOFBY
Other OTC0.84
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eric Wang
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 680 George Street Sydney NSW Australia 2000
- IPO Date
- Apr 14, 2022
- Website
- ecofibre.com
- Similar Companies
- Business
- Ecofibre Limited is an Australian biotechnology company specializing in the research, production, and sale of hemp-derived products and polymer-based industrial materials. Founded in 2009 and headquartered in Sydney, Australia, Ecofibre operates primarily in the United States and Australia through four business segments: Ecofibre Advanced Technologies, Ananda Health, Ecofibre Genetics, and EOF Bio. The company offers a diverse portfolio including high-performance yarns and fibers; cannabinoid-based health and wellness products for human and pet consumption under the Ananda Health brand; hemp-derived food products marketed mainly in Australia via Ananda Food; and hemp seed genetics with over 300 cannabis landraces from more than 25 countries. Additionally, Ecofibre Advanced Technologies focuses on polymer compounding, sustainable materials, and performance yarn extrusion, while EOF Bio is a clinical-stage biotechnology business developing cannabinoid-based pharmaceuticals targeting women's health and gynecological diseases. In recent developments, Ecofibre completed the acquisition of TexInnovate, a portfolio of five businesses with expertise in high-performance textile technologies, to expand its Hemp Black segment. This acquisition supports Hemp Black’s vision of embedding sustainable technology across industries such as apparel, personal protection, military, healthcare, and travel. In July 2023, Ecofibre spun off EOF Bio to focus on commercializing a growing portfolio of cannabinoid drug patents. The company also continues to innovate in plant-based wellness product categories addressing health issues including blood sugar management, women's health, and immune support. Ecofibre maintains operations through a vertically integrated supply chain encompassing sustainable hemp cultivation in the U.S. and production facilities in both countries, targeting consumers, retail pharmacies, and independent pharmacy chains. Ecofibre's portfolio reflects its focus on sustainability, innovation, and diversification across polymer technology, natural health care, hemp food, and pharmaceutical segments, with ongoing expansion and integration initiatives to capture market opportunities in the U.S. and Australian markets. The company combines proprietary genetics, advanced manufacturing capabilities, and clinical drug development to position itself at the forefront of the hemp biotechnology and specialty materials industry. Its strategic alliances, acquisitions, and recent corporate spin-offs demonstrate Ecofibre's commitment to broadening its product offering and commercial footprint in the rapidly evolving hemp and cannabinoid market.